News: Jun 2018

node teaser

Dr Rubin’s drug screening assay is progressing well

30 June 2018

Dr Rubin’s drug screening study is going well. His team successfully transferred the screen to the Case Western Reserve Drug Screening Core where they screened a 1400 compound repurposed chemotherapy library and a 50,000 molecule Chembridge drug-like compound library. They are in the process of running compounds identified in the primary screen through their pipeline to focus on the most promising molecules for drug development. Dr Rubin is optimistic that this approach will yield active...

node teaser

A long walk for EHE!

29 June 2018

At the end of June Nicola Henderson’s very close friend Rachel Undy and her work colleague Jim Babington were taking on the Cotswold Way Challenge for EHE. This is a 100km walk across rough and hilly terrain in the UK. The weather was also very hot making it an extra tough challenge, with Rachel suffering severe heat stroke! But helping EHE drove both Jim and Rachel on. Jim noted “ What surprised me was how hard it was mentally to keep moving during the dark hours when every step was...

node teaser

EHE well represented at ASCO 2018 in Chicago

10 June 2018

The EHE Foundation was well presented at the 2018 ASCO Conference in Chicago by Jane Gutkovich (Director of Research), Lisa De Young (Director of Patient Liaison Services), and Denise Robinson (Research Manager). We were also delighted to see many of our Advisory Board members and other sarcoma specialists present at the EHE meeting organised by the EHE Foundation. A lot of ground was covered at the meeting, with even more EHE issues discussed at different venues over the duration of the...

node teaser

The Mekinist (trametinib) trial moves to Phase 2

10 June 2018

Dr Rubin was delighted to be able to report that the clinical trial of mekinist has moved into phase 2. “ They said we couldn’t do it but we did. Thanks to Dr Scott Schuetze (University of Michigan) and the good people at SARC, we successfully launched the first prospective clinical trial of EHE patients. The trial is examining the effect of trametinib, a MEK inhibitor as a treatment for progressive EHE. MEK is a signal transduction molecule that is activated as a result of TAZ-CAMTA1...